Newsroom > Articles


Medexprim is recognized by the firm Elinoï as one of the 50 startups to apply for in 2023.

With 20 recruitments in 2022 and 20 new recruitments planned in 2023, Medexprim relies on three axes to serve its growth:

  • Diversity within the team: the workforce of 45 employees includes 8 nationalities and 55% of them are women, especially engineers and developers, which is exceptional in the Tech sector.
  • Set up of an “Operations Steering Committee”: complementary to the Board of Directors, this steering tool allows the company’s project to be co-directed with all departments, breaking away from a top-down logic.
  • Definition of strong common values: the team has worked together to define Medexprim’s values and to make them live on a daily basis. Ambition, Cooperation, Benevolence and Innovation thus constitute a common compass, both internally and externally.

Mathilde Waringo, Medexprim’s HR Manager: “We aim to bring together the best talents. This means hiring the best candidates, regardless of gender, origin, sexual orientation, age or disability status, and creating the conditions for them to flourish, progress and increase their autonomy. Bringing together different profiles is a guarantee of richness and creativity, which undeniably feeds our ability to innovate for our clients.” 

Elinoï is a recruitment firm created in 2013 in Paris. Building on a deep knowledge of candidate and company culture, Elinoï cultivates a talent pool to connect the right profiles with growth companies. In 2022, Elinoï publishes the 4th edition of its selection of “50 start-ups to apply to”.

Elinoï’s Selection

French version of the PR

About Medexprim:
Medexprim is Europe’s leading provider of secure imaging and clinical data extraction to accelerate medical research. As a real-world data specialist, we build bridges between leading academic hospitals and pharmaceutical, AI and medical device companies. In compliance with the GDPR, we help hospitals drive their own clinical research strategy and extract value from their data, through our software and services designed with and for clinicians. We provide our partners with secure access to regulatory-grade data. Medexprim aims to build multicentric disease-specific data lakes to serve oncology, neurology and cardiology. We help solve the “one patient, one disease, one treatment” equation to develop precision medicine for better care.

Medexprim Press contact: Anne-Sophie Labeta

3 questions to Coralie Carron

As a Ph.D. holder in Cellular and Molecular Biology, Coralie Carron assumes the pivotal…

CIAN: Cohort Imaging Analytics Network

Medexprim enables the aggregation, curation and enrichment of multicentric and multimodal cohorts of Real-World…

💡Scientific Insights – Read Samuel Boucher’s Take on the future…

Medexprim’s researchers and engineers contribute daily to the advancement of scientific research. Our researchers…

PR – Medexprim partners with Avicenna.AI to help validate their…

Medexprim, the European leader in multimodal Real-World datasets for clinical research, is pleased to…